Clinical Scorecard: Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?
At a Glance
| Category | Detail |
|---|---|
| Condition | Cell and Gene Therapy |
| Key Mechanisms | Transformative potential for serious diseases, high manufacturing costs, complex delivery pathways. |
| Target Population | Patients requiring advanced therapies for serious diseases. |
| Care Setting | Routine care transitioning from clinical trials. |
Key Highlights
- High manufacturing costs restrict patient access to therapies.
- Need for assessing long-term value rather than just upfront costs.
- Importance of treating patients earlier in the disease process.
- Expansion of delivery methods beyond specialist centers.
- Collaboration among manufacturers, regulators, and healthcare systems is essential.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with serious diseases requiring cell and gene therapies.
Access to therapies is limited by costs and delivery complexities.
Clinical Best Practices
- Reduce production costs for therapies.
- Focus on long-term value assessment.
- Collaborate across sectors to improve access.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
